EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Evaluation of the Epitogen Lyme Detect IgG ELISA: a novel peptide multiplexing approach

Tiehui Wang iD, Alex Wang, Rodanthi Zindrili iD, Elena Melis iD, Swapna Guntupalli, Robin Brittain-Long, Mirela Delibegovic iD, Christopher J Secombes iD, Nimesh Mody iD, Sally Mavin iD, Ralfs Buks iD

Microbiology Spectrum · 05.12.2024 · 12 (12)

DOI: 10.1128/spectrum.01675-24 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Microbiology Spectrum, erschienen am 05.12.2024. Verfasst von Tiehui Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: EpitogenX Ltd, Foresterhill Health Campus, Aberdeen, United Kingdom. Hauptthemen laut MEDLINE: Lyme Disease, Immunoglobulin G, Antibodies, Bacterial, Borrelia burgdorferi. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lyme Borreliosis (LB), or Lyme disease, is a growing health concern caused by Borrelia burgdorferi sensu lato (Bbsl) bacteria transmitted through tick bites, and untreated cases can lead to severe health complications. Existing serology tests, while valuable, have low sensitivity in early infection stages where diagnosis is vital, interpretation variability, and false positives from cross-reactivity, while direct detection methods also suffer from low sensitivity, due to the inconsistent presence of Bbsl components in clinical samples. This study validated the diagnostic performance of the novel Epitogen Lyme Detect IgG enzyme-linked immunosorbent assay (ELISA) based on scaffold-displayed peptide antigens, using 120 specific immunodominant epitopes selected from 37 antigenic bacterial proteins corresponding to the main pathogenic Bbsl genospecies. Using 220 serum samples from Scottish patients with early, late, and disseminated LB, the assay’s sensitivity was compared with that of the LIAISON Borrelia IgG CLIA, while specificity was assessed with 198 control samples, including healthy individuals and patients with diseases that are humorally similar. The Epitogen Lyme Detect IgG assay demonstrated comparable performance to the LIAISON Borrelia IgG in disseminated and late LB (Lyme neuroborreliosis, acrodermatitis chronica atrophicans, and Lyme arthritis). Notably, the Epitogen Lyme Detect IgG showed significantly higher sensitivity in patients with suspected erythema migrans, while maintaining high specificity. The Epitogen Lyme Detect IgG ELISA offers a promising advancement in LB diagnostics, demonstrating its potential for more accurate and timely diagnosis, particularly in the early stages of LB infection. IMPORTANCE Lyme Borreliosis (LB), caused by Borrelia burgdorferi sensu lato bacteria, poses significant health risks if undiagnosed or diagnosed late. Current diagnostic tests have limitations, especially in early-stage detection. This study validates the Epitogen Lyme Detect IgG enzyme-linked immunosorbent assay, demonstrating superior sensitivity in early LB detection while maintaining high specificity. The Epitogen Lyme Detect IgG comprises a suite of 120 immunodominant IgG epitopes/peptides from 37 bacterial antigens, covering the main LB-causing species: Borrelia burgdorferi sensu stricto , Borrelia afzelii , Borrelia garinii , and Borrelia mayonii . The novel design of multiplexing peptide antigens onto a scaffold to facilitate expression, correct folding, and orientation of the relevant peptides offers a promising advancement, potentially leading to more accurate and timely LB diagnoses and improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lyme DiseaseImmunoglobulin GAntibodies, BacterialBorrelia burgdorferiBorrelia burgdorferi GroupHumansEnzyme-Linked Immunosorbent AssaySensitivity and SpecificityAntigens, BacterialPeptidesEpitopes

Stichwörter der Autor:innen

Lyme borreliosisdiagnosticsimmunodominancepeptide multiplexvalidation

Substanzen

Immunoglobulin GAntibodies, BacterialAntigens, BacterialPeptidesEpitopes

Autor:innen und Institutionen

  • EpitogenX Ltd, Foresterhill Health Campus, Aberdeen, United Kingdom.
  • University of Aberdeen, Aberdeen, United Kingdom.
  • Scottish Lyme Disease and Tick-Borne Infections Reference Laboratory, Raigmore Hospital, Inverness, United Kingdom.
  • Department of Infectious Diseases, NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.
  • Aberdeen Cardiovascular and Diabetes Centre, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom.

ORCID-Profile: Tiehui Wang, Rodanthi Zindrili, Elena Melis, Mirela Delibegovic, Christopher J Secombes, Nimesh Mody, Sally Mavin, Ralfs Buks

Zitieren

APA

Wang, T., Wang, A., Zindrili, R., Melis, E., Guntupalli, S., Brittain-Long, R., Delibegovic, M., Secombes, C. J., Mody, N., Mavin, S., & Buks, R. (2024). Evaluation of the Epitogen Lyme Detect IgG ELISA: a novel peptide multiplexing approach. Microbiology Spectrum, 12(12). https://doi.org/10.1128/spectrum.01675-24

Vancouver

Wang T, Wang A, Zindrili R, Melis E, Guntupalli S, Brittain-Long R, et al. Evaluation of the Epitogen Lyme Detect IgG ELISA: a novel peptide multiplexing approach. Microbiology Spectrum. 2024;12(12). doi:10.1128/spectrum.01675-24

BibTeX
@article{Wang2024,
  author = {Wang, Tiehui and Wang, Alex and Zindrili, Rodanthi and Melis, Elena and Guntupalli, Swapna and Brittain-Long, Robin and Delibegovic, Mirela and Secombes, Christopher J and Mody, Nimesh and Mavin, Sally and Buks, Ralfs},
  title = {Evaluation of the Epitogen Lyme Detect IgG ELISA: a novel peptide multiplexing approach},
  journal = {Microbiology Spectrum},
  year = {2024},
  volume = {12},
  number = {12},
  doi = {10.1128/spectrum.01675-24}
}
Kostenlos starten →